Pancreatic cancer death rates in whites and blacks have gone in opposite directions over the past several decades in the United States, with the direction reversing in each ethnicity during those years. Researchers involved with this new study say the rising and falling rates are largely unexplainable by known risk factors.
A small preliminary study suggests that a simple blood test based on detection of tiny epigenetic alterations may reveal the earliest signs of pancreatic cancer.
An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, according to recently presented research.
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease.
Pancreatic cancer biomarkers have been definitively validated in saliva. This finding may be a major step toward enabling oncologists to detect pancreatic cancer with a simple risk assessment.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|